A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
NCT ID: NCT02921828
Last Updated: 2022-07-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1149 participants
OBSERVATIONAL
2015-04-30
2015-12-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. Planned duration of the surveillance Anticipated to be 2 years and 6 months from the start date of release of Pomalyst
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea
NCT03288974
An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice
NCT02902900
Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma
NCT01177735
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
NCT01745588
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
NCT02188368
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Multiple myeloma patients who received Pomalyst
Among relapsed or refractory multiple myeloma patients, all patients who received Pomalyst will be targeted in this surveillance.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jinshu Cho
Role: STUDY_DIRECTOR
Celgene
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - Japan
No City Provided, New Jersey, United States
Shinko Hospital
Kobe, Hyōgo, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-Celgene-JP-PMS-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.